These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 22340451)

  • 1. The Genuair® inhaler: a novel, multidose dry powder inhaler.
    Chrystyn H; Niederlaender C
    Int J Clin Pract; 2012 Mar; 66(3):309-17. PubMed ID: 22340451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peak inspiratory flow through the Genuair inhaler in patients with moderate or severe COPD.
    Magnussen H; Watz H; Zimmermann I; Macht S; Greguletz R; Falques M; Jarreta D; Garcia Gil E
    Respir Med; 2009 Dec; 103(12):1832-7. PubMed ID: 19651504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lung deposition of aclidinium bromide from Genuair, a multidose dry powder inhaler.
    Newman SP; Sutton DJ; Segarra R; Lamarca R; de Miquel G
    Respiration; 2009; 78(3):322-8. PubMed ID: 19451700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genuair(®) in chronic obstructive pulmonary disease: a novel, user-friendly, multidose, dry-powder inhaler.
    der Palen Jv
    Ther Deliv; 2014 Jul; 5(7):795-806. PubMed ID: 25287386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical relevance of dry powder inhaler performance for drug delivery.
    Demoly P; Hagedoorn P; de Boer AH; Frijlink HW
    Respir Med; 2014 Aug; 108(8):1195-203. PubMed ID: 24929253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Respimat®, first Soft Mist™ inhaler: new perspectives in the management of COPD].
    Henriet AC; Marchand-Adam S; Mankikian J; Diot P
    Rev Mal Respir; 2010 Dec; 27(10):1141-9. PubMed ID: 21163393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aclidinium bromide for the treatment of chronic obstructive pulmonary disease.
    Cazzola M; Page CP; Matera MG
    Expert Opin Pharmacother; 2013 Jun; 14(9):1205-14. PubMed ID: 23566013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhalatory therapy training: a priority challenge for the physician.
    Melani AS
    Acta Biomed; 2007 Dec; 78(3):233-45. PubMed ID: 18330086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In Vitro Dosing Performance of the ELLIPTA® Dry Powder Inhaler Using Asthma and COPD Patient Inhalation Profiles Replicated with the Electronic Lung (eLung™).
    Hamilton M; Leggett R; Pang C; Charles S; Gillett B; Prime D
    J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):498-506. PubMed ID: 26372465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Disease Severity in Asthma and Chronic Obstructive Pulmonary Disease on Inhaler-Specific Inhalation Profiles Through the ELLIPTA® Dry Powder Inhaler.
    Prime D; de Backer W; Hamilton M; Cahn A; Preece A; Kelleher D; Baines A; Moore A; Brealey N; Moynihan J
    J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):486-97. PubMed ID: 26372467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aclidinium bromide twice daily for the treatment of chronic obstructive pulmonary disease: a review.
    Jones P
    Adv Ther; 2013 Apr; 30(4):354-68. PubMed ID: 23553509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novolizer: how does it fit into inhalation therapy?
    Magnussen H
    Curr Med Res Opin; 2005; 21 Suppl 4():S39-46; discussion S47. PubMed ID: 16138944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The ELLIPTA® Dry Powder Inhaler: Design, Functionality, In Vitro Dosing Performance and Critical Task Compliance by Patients and Caregivers.
    Grant AC; Walker R; Hamilton M; Garrill K
    J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):474-85. PubMed ID: 26372466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aclidinium bromide for the treatment of chronic obstructive pulmonary disease.
    Gupta V; Singh D
    Expert Rev Respir Med; 2012 Dec; 6(6):581-8. PubMed ID: 23234445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term safety and efficacy of twice-daily aclidinium bromide in patients with COPD.
    Gelb AF; Tashkin DP; Make BJ; Zhong X; Garcia Gil E; Caracta C;
    Respir Med; 2013 Dec; 107(12):1957-65. PubMed ID: 23916502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genuair
    Magnussen H; Fyrnys B; Greguletz R
    COPD; 2019 Apr; 16(2):196-205. PubMed ID: 31264482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvements in patient-reported outcomes: A prospective, non-interventional study with aclidinium bromide for treatment of COPD.
    Marth K; Schuller E; Pohl W
    Respir Med; 2015 May; 109(5):616-24. PubMed ID: 25796962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pilot study of bronchodilator response to inhaled albuterol delivered by metered-dose inhaler and a novel dry powder inhaler.
    Kemp JP; Hill MR; Vaughan LM; Meltzer EO; Welch MJ; Ostrom NK
    Ann Allergy Asthma Immunol; 1997 Oct; 79(4):322-6. PubMed ID: 9357377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of the development of Respimat Soft Mist Inhaler.
    Dalby R; Spallek M; Voshaar T
    Int J Pharm; 2004 Sep; 283(1-2):1-9. PubMed ID: 15363496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro dose comparison of Respimat
    Ciciliani AM; Langguth P; Wachtel H
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1565-1577. PubMed ID: 28603412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.